Average per-patient Phase 3 trial cost across 1,680 trials (PhRMA and Battelle, as cited by Health Advances)

$42,000

USD per patient, US

“an analysis published by PhRMA and Battelle estimated average per patient phase 3 trial costs to be $42,000 based on an analysis of 1,680 phase 3 trials”

Health Advances, Orphan Drug Development: What are the Real Costs? (10 April 2019; read from an Internet Archive copy), 2019-04

Kind of source

Named press report

Read on

2026-11-06

Daily check

Source re-read on 2026-11-06 needs a browser (PDF or protected page)

What to know

The comparison figure Health Advances sets beside orphan trials.